Customize your JAMA Network experience by selecting one or more topics from the list below.
Perlman EM, Greenberg PB, Browning D, Friday RP, Miller JW. Solving the Hydroxychloroquine Dosing Dilemma With a Smartphone App. JAMA Ophthalmol. 2018;136(2):218–219. doi:10.1001/jamaophthalmol.2017.6076
Hydroxychloroquine retinopathy (HCR) is a potentially blinding disease. Once HCR is detected, there is no treatment and the disease often continues to progress, even when the medication is stopped. Hence, primary prevention by appropriate dosing of hydroxychloroquine offers the best chance of minimizing the risk of HCR.
This strategy remains challenging in practice as up to 56% of patients receive hydroxychloroquine at doses that place them at higher risk for HCR.1 A key reason is disagreement in how to calculate dosages of hydroxychloroquine.2,3 There are 2 methods: one uses ideal body weight (IBW); the other uses actual body weight (ABW). The IBW method assumes that hydroxychloroquine is stored mostly in lean tissue.2 The daily dose must be normalized by lean body mass. This makes the calculation more complicated than the ABW method, which assumes that the drug is distributed evenly in muscle, skin, and fat.3 We describe a free smartphone app—DoseChecker—that can rapidly calculate the optimal weekly dose of hydroxychloroquine using elements of both methods.
Create a personal account or sign in to: